Evidence map›Paper›PMID 41090691›Full record

ArticleCancer medicine2025

Real-World Treatment Patterns and Outcomes of Zanubrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (CLL/SLL).

Margaret Li Krackeler, Bryant H Chee, Arthur K Orchanian, Raymond Liu, Lisa Law, Shiyun Zhu, Zheng Zhu, Lori C Sakoda, Susan Buchanan, Marjan Massoudi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Margaret Li KrackelerDepartment of Hematology Oncology, Kaiser Permanente San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-8151-9784
Bryant H CheeDepartment of Internal Medicine, Kaiser Permanente San Francisco, San Francisco, California, USA.
Arthur K OrchanianDepartment of Internal Medicine, Kaiser Permanente San Francisco, San Francisco, California, USA.
Raymond LiuDepartment of Hematology Oncology, Kaiser Permanente San Francisco, San Francisco, California, USA.
Lisa LawDepartment of Hematology Oncology, Kaiser Permanente Roseville, Roseville, California, USA.ORCID https://orcid.org/0000-0001-7343-8212
Shiyun ZhuDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Zheng ZhuDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Lori C SakodaDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Susan BuchananBeOne Medicines Ltd, San Carlos, California, USA.
Marjan MassoudiBeOne Medicines Ltd, San Carlos, California, USA.
Alfredo LopezDepartment of Hematology Oncology, Kaiser Permanente San Francisco, San Francisco, California, USA.
Jahan TavakoliDepartment of Hematology Oncology, Kaiser Permanente San Francisco, San Francisco, California, USA.

Funding

BeOne Medicines
6 · The paper itself

Abstract

Zanubrutinib is a next-generation selective Bruton's tyrosine kinase inhibitor (BTKi) with superior efficacy and lower cardiotoxicity rates seen in clinical trials over first-generation ibrutinib in CLL/SLL patients. We present real-world treatment patterns based on a practice change from ibrutinib to zanubrutinib in CLL/SLL patients in an integrated community oncology practice. We retrospectively analyzed adult patients who filled at least 3 months of zanubrutinib at Kaiser Permanente Northern California. Treatment patterns, adverse events (AE), and mortality were reported. Two hundred eighty-one patients received zanubrutinib; 190 patients switched from ibrutinib. Similar AE rates were seen with both BTKis, with a lower proportion of patients with treatment-limiting AEs and lower cardiac AE rates with zanubrutinib. Most patients remained on zanubrutinib at the end of data collection without treatment-related deaths reported. In the real-world setting, zanubrutinib is effective and safe in patients with or without prior ibrutinib use, with low cardiotoxicity and AE rates, though data was limited by a difference in follow-up time.

Indexed as

Antineoplastic AgentsLeukemia, Lymphocytic, Chronic, B-CellPiperidinesPractice Patterns, Physicians'Protein Kinase InhibitorsPyrazolesPyrimidinesAdenineAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesAdenineAntineoplastic AgentsibrutinibPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidineszanubrutinibchronic lymphocytic leukemiaibrutinibreal‐world datazanubrutinib

Identifiers

PMID41090691
PMCPMC12522175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.